Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (501)	8/3/1999 11:03:00 PM
From: tommysdad	Read Replies (2) \| Respond to of 579

Article in BioWorld Today on the deal. Quotes a guy from Merck (Fisher) as saying that all contractual obligations will be honored (read: Lilly keeps the compounds) and that their real interest in the company was not any drugs in the pipe but the technology and the staff. Which I interpret to mean that MRK will put the screws to PFE, and that most of the people at SIBI have pretty good job security as MRK employees, if they want it. Might have to trade in some of their titles, though. (<<Sorry, didn't show sufficient respect for your post with my last answer>> At least you didn't compare any stock to my butt.)